Plain-English translation of NCT05533775 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called to treat young people with a type of blood cancer that has either returned after treatment or stopped responding to previous treatments. Some participants will receive alone, while others will receive it combined with standard chemotherapy drugs. The trial aims to find out whether this medication is safe and how well it works.
Many young people with this type of blood cancer don't respond well to standard treatments, or their cancer comes back after treatment. This trial is exploring whether this medication could offer a new option for these patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
Participants will visit the clinic regularly for treatment and monitoring over several months. Some participants will receive the new medication alone in cycles lasting about 3 weeks each, for up to 12 cycles. Others will receive the medication combined with standard chemotherapy drugs for up to 3 cycles. At each visit, you'll receive the medication and have blood tests and scans to check how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States